default author photo

Patrick Neven

KU Leuven - Department of Gynecologic Oncology

SCHOLARLY PAPERS

6

DOWNLOADS

235

TOTAL CITATIONS

0

Scholarly Papers (6)

Actions:
Email selected abstracts
1.

Pooled Analysis of Safety and Dose Reductions in the MONALEESA-2, -3, and -7 Phase III Trials on Ribociclib Plus Endocrine Therapy to Treat Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Number of pages: 22 Posted: 29 Oct 2020
Howard Burris, Arlene Chan, Aditya Bardia, J. Thaddeus Beck, Joohyuk Sohn, Patrick Neven, Debu Tripathy, Seock-Ah Im, Stephen Chia, Francisco J. Esteva, Lowell Hart, Juan Pablo Zarate, Antonia Ridolfi, Karen Rodriguez-Lorenc and Denise A. Yardley
Tennessee Oncology - Sarah Cannon Research Institute, Curtin University, Harvard Medical School - Massachusetts General Hospital Cancer Center, Highlands Oncology Group, Yonsei University Health System - Severance Hospital, KU Leuven - Department of Gynecologic Oncology, University of Texas at Houston - Department of Breast Medical Oncology, Seoul National University - Department of Internal Medicine, BC Cancer Agency (BCCA), NYU Langone Health, Sarah Cannon Research Institute - Florida Cancer Specialists, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation and Tennessee Oncology - Sarah Cannon Research Institute
Downloads 82 (790,029)

Abstract:

Loading...

ribociclib, breast cancer, CDK4/6 inhibitor, endocrine therapy

2.

Adjuvant Ovarian Function Suppression and Aromatase Inhibitors in Premenopausal Patients with Hormone Receptor And Her2 Positive Breast Cancer, by Timing of Chemotherapy and Trastuzumab and Response to Neoadjuvant Therapy

Number of pages: 22 Posted: 16 Jul 2025
Ayelet Shai, Hans Wildiers, Claudio Vernieri, Katarzyna Pogoda, Barbro Linderholm, Matteo Lambertini, Leonor Matos, Eleonora De Maio D’Esposito, Nawale Hajjaji, Erika Matos, Lucia Gonzalez-Cortijo, Giuseppe Fotia, Ana Fortuna, Tal Sella, Helena Gouveia, Laurent Rosset, Anastasia Constantinidou, Eurydice Angeli, Irfan Cicin, Vivianne C.G. Tjan-Heijnen, Natacha Ruyssers, Sofie Demasure, Areen Abu Remilah, Greet Huygh, Shani Paluch-Shimon, Edoardo Chiappe, Natali Shirron, Patrick Neven, Mehmet Artac, Bilgesah Kilictas, Jalal Baranseh, Elena Vicente-Rubio, Mustafa Atci, Ottavia Amato and Frederieke van Duijnhoven
Technion-Israel Institute of Technology - Rambam Health Care Campus, KU Leuven - University Hospitals Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Gothenburg - Sahlgrenska University Hospital, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), affiliation not provided to SSRN, affiliation not provided to SSRN, Université de Lille - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Institute of Oncology, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Santa Maria Local Health Unit, affiliation not provided to SSRN, affiliation not provided to SSRN, HFR Fribourg Cantonal Hospital, Bank of Cyprus Oncology Centre, Institut National de la Santé et de la Recherche Médicale (INSERM), Istinye University, Maastricht University, AZ Turnhout, AZ Groeninge, Hebrew University of Jerusalem - Shaare Zedek Medical Center, affiliation not provided to SSRN, Hebrew University of Jerusalem - The Sharett Institute of Oncology, IRCCS Ospedale Policlinico San Martino, Technion-Israel Institute of Technology - Rambam Health Care Campus, KU Leuven - Department of Gynecologic Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Technion-Israel Institute of Technology - Rambam Health Care Campus, affiliation not provided to SSRN, Istinye University, European Commission, Joint Research Centre and Netherlands Cancer Institute
Downloads 52 (1,041,696)

Abstract:

Loading...

Ovarian function suppression, HER2 positive, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, LHRH agonists, neoadjuvant, residual disease, pathological complete response

3.

Association of Body Mass Index with Clinicopathological Features and Survival in Patients with Primary Invasive Lobular Breast Cancer

Number of pages: 20 Posted: 26 Apr 2023
Karen Van Baelen, Ha-Linh Nguyen, Anne-Sophie Hamy-Petit, François Richard, Maria Margarete Karsten, Guilherme Nader Marta, Peter Vermeulen, Aullene Toussaint, Fabien Reyal, Anne Vincent-Salomon, Luc Dirix, Adam David Dordevic, Evandro de Azambuja, Denis Larsimont, Ottavia Amato, Marion Maetens, Maxim De Schepper, Tatjana Geukens, Sileny N. Han, Thaïs Baert, Kevin Punie, Hans Wildiers, Ann Smeets, Ines Nevelsteen, Giuseppe Floris, Elia Biganzoli, Patrick Neven and Christine Desmedt
KU Leuven, KU Leuven, Institut Curie - Department of Medical Oncology, KU Leuven, Charité - Universitätsmedizin Berlin - Department of Gynaecology, Université Libre de Bruxelles (ULB) - Institute Jules Bordet, University of Antwerp - Center for Oncological Research (CORE), Institut Curie - Department of Medical Oncology, PSL Research University - Institut Curie, Université PSL - Institut Curie, University of Antwerp - Center for Oncological Research (CORE), Charité - Universitätsmedizin Berlin - Department of Gynaecology, Université Libre de Bruxelles (ULB) - Institute Jules Bordet, Université Libre de Bruxelles (ULB) - Institute Jules Bordet, Université Libre de Bruxelles (ULB) - Institute Jules Bordet, KU Leuven, KU Leuven, KU Leuven - Department of Oncology, KU Leuven - Department of Gynecologic Oncology, KU Leuven - Department of Gynecologic Oncology, KU Leuven - University Hospitals Leuven, KU Leuven - University Hospitals Leuven, KU Leuven - University Hospitals Leuven, KU Leuven - University Hospitals Leuven, KU Leuven - University Hospitals Leuven, University of Milan - Department of Biomedical and Clinical Sciences, KU Leuven - Department of Gynecologic Oncology and KU Leuven
Downloads 44 (1,133,231)

Abstract:

Loading...

Invasive lobular breast cancer, body mass index, prognostic factors, survival analyses

4.

Metastases of Primary Mixed No-Special Type and Lobular Breast Cancer Display an Exclusive Lobular Histology

Number of pages: 13 Posted: 29 Jan 2024
Gitte Zels, Karen Van Baelen, Maxim De Schepper, Kristien Borremans, Tatjana Geukens, Edoardo Isnaldi, Hava Izci, Sophia Leduc, Amena Mahdami, Marion Maetens, Ha-Linh Nguyen, Anirudh Pabba, François Richard, Josephine Van Cauwenberge, Ann Smeets, Ines Nevelsteen, Patrick Neven, Hans Wildiers, Wouter Van Den Bogaert, Giuseppe Floris and Christine Desmedt
KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven, KU Leuven - University Hospitals Leuven, KU Leuven - University Hospitals Leuven, KU Leuven - Department of Gynecologic Oncology, KU Leuven - University Hospitals Leuven, KU Leuven - University Hospitals Leuven, KU Leuven - University Hospitals Leuven and KU Leuven
Downloads 37 (1,222,651)

Abstract:

Loading...

mixed invasive breast cancer of no-special type and invasive lobular cancer, metastatic disease, E-cadherin

5.

The Impact of Breast Cancer Surgery on Sexual Functioning: A Retrospective Online Survey “Do scars really matter?”

Number of pages: 20 Posted: 14 Jan 2026
Nynke Elisabeth Willers, Paul Enzlin, Ann Smeets, Ines Nevelsteen, Tineke Vandenbroucke, Hannah De Messemaeker, Saskia M. Willers, Jan Decloedt, Patrick Neven and Sileny N. Han
KU Leuven - University Hospitals Leuven, affiliation not provided to SSRN, KU Leuven - University Hospitals Leuven, KU Leuven - University Hospitals Leuven, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, AZ Sint-Blasius, KU Leuven - Department of Gynecologic Oncology and KU Leuven - Department of Gynecologic Oncology
Downloads 20 (1,448,301)

Abstract:

Loading...

Breast cancer
Sexuality 
Endocrine therapy

6.

Mortality and Major Adverse Cardiac Events in Women With Breast Cancer Receiving Radiotherapy: A 10-Year Cohort Study of Patients and Population Controls

Posted: 08 Dec 2021
Johanna EJ Jacobs, Wouter L’Hoyes, Lieselotte Lauwens, Caroline Weltens, Jens-Uwe Voigt, Hans Wildiers, Patrick Neven, Joerg Herrmann, Lutgarde Thijs, Jan A. Staessen, Stefan Janssens and Lucas Van Aelst
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, UZ Leuven, affiliation not provided to SSRN, KU Leuven - University Hospitals Leuven, KU Leuven - Department of Gynecologic Oncology, Mayo Clinic, affiliation not provided to SSRN, Non-Profit Research Institute Alliance for the Promotion of Preventive Medicine, KU Leuven - Division of Cardiology and KU Leuven - Division of Cardiology

Abstract:

Loading...

Cardiovascular diseases - Cardio-oncology - Radiation therapy - Breast cancer - Risk factors - Epidemiology